On April, 24 Edwards Lifesciences Corporation (EW) EPS Estimated At $1.10

Doris Richards
April 15, 2018

(V) by 4.42% based on its latest 2017Q4 regulatory filing with the SEC. The institutional investor owned 77,325 shares of the medical research company's stock after selling 11,080 shares during the period. The institutional investor held 74,690 shares of the movies and entertainment company at the end of 2017Q4, valued at $1.72M, down from 182,797 at the end of the previous reported quarter. The stock increased 1.32% or $1.81 during the last trading session, reaching $139.28. The shares were sold at an average price of $122.24, for a total value of $1,466,880.00.

Currently, Mr. Jeanluc, has ownership of 38,840 shares, which accounts for 0.02% of Edwards Lifesciences Corp's market cap. Envestnet Asset Management Inc. now owns 199,509 shares of the medical research company's stock valued at $22,485,000 after buying an additional 21,929 shares during the period. Cim Llc who had been investing in Edwards Lifesciences Corp for a number of months, seems to be bullish on the $29.32 billion market cap company. Commonwealth Equity Services Inc now owns 22,872 shares of the medical research company's stock worth $2,500,000 after acquiring an additional 1,117 shares in the last quarter. About 1.20M shares traded.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 3.28% during trading on Thursday, reaching $95.23. EW outperformed by 32.51% the S&P500.

Investors sentiment decreased to 1.19 in 2017 Q4. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.80 and a quick ratio of 1.41. It dived, as 48 investors sold LOW shares while 437 reduced holdings. 141 funds opened positions while 552 raised stakes. Blackrock accumulated 286.60 million shares or 0.83% of the stock. 585.84 million shares or 0.67% less from 589.78 million shares in 2017Q3 were reported. Stevens First Principles, a California-based fund reported 108 shares. Virtus Invest Advisers Incorporated holds 0% or 1,740 shares. Pacer Advisors Inc. boosted its holdings in shares of Edwards Lifesciences by 10.4% in the 3rd quarter. Also, VP Larry L. Wood sold 6,300 shares of the stock in a transaction that occurred on Tuesday, January 16th. Arizona State Retirement Systems holds 0.03% of its portfolio in Chemical Financial Corporation (NASDAQ:CHFC) for 51,226 shares. MN now owns 2,116,119 shares of the medical research company's stock valued at $238,508,000 after buying an additional 11,675 shares during the last quarter. Mufg Americas Holdg holds 0% of its portfolio in Chemical Financial Corporation (NASDAQ:CHFC) for 1,224 shares. Donaldson Mngmt Llc has invested 0.83% in Wells Fargo & Company (NYSE:WFC). Nomura Asset Mngmt holds 0.01% or 20,428 shares. Lipe & Dalton stated it has 1.14% in Visa Inc.

Since November 17, 2017, it had 0 insider buys, and 1 insider sale for $292,234 activity. The stock was sold at an average price of $134.78, for a total transaction of $539,120.00.

A number of other hedge funds also recently modified their holdings of EW. "Buy" rating has 12, "Sell" are 0, while 3 are "Hold". Therefore 43% are positive. Regal Entertainment Group had 67 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned "Buy" rating on Thursday, March 22 by Canaccord Genuity. The stock of Host Hotels & Resorts, Inc. Canaccord Genuity restated a "buy" rating and issued a $174.00 price objective (up previously from $140.00) on shares of Edwards Lifesciences in a research report on Friday, February 2nd. In Friday, February 2 report Morgan Stanley maintained the stock with "Overweight" rating. The stock now has a consensus rating of "Buy" and an average target price of $145.92. The stock rating was maintained by Barclays Capital with "Equal-Weight" on Wednesday, October 25. The stock has "Overweight" rating by JP Morgan on Friday, August 14. On Thursday, December 7 the rating was maintained by BMO Capital Markets with "Buy". The stock has "Outperform" rating by Cowen & Co on Friday, October 9. Guggenheim initiated Visa Inc.

Analysts at Leerink Swann cut their Q1 2018 EPS estimates for Edwards Lifesciences in a research report issued on Wednesday, April 11th. During the same quarter last year, the business posted $0.75 earnings per share. analysts anticipate that Edwards Lifesciences Corp will post 4.53 EPS for the current fiscal year. If earnings per share of $1.10 is revealed the profit of EW could be $231.57M giving it 31.33 P/E.

Atlantic Trust Group Llc, which manages about $23.58B US Long portfolio, decreased its stake in Hess Midstream Partners Lp by 19,214 shares to 80,786 shares, valued at $1.60 million in 2017Q4, according to the filing. Therefore 79% are positive. 28 are the (NYSE:EW)'s analyst reports since October 25, 2017 according to StockzIntelligence Inc. The stock has "Outperform" rating by Credit Suisse on Friday, February 5. The rating was maintained by Citigroup on Wednesday, April 27 with "Sell".

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on April, 24. The rating was maintained by BTIG Research on Wednesday, July 27 with "Buy". The stock of Edwards Lifesciences Corporation (NYSE:EW) has "Buy" rating given on Friday, February 2 by RBC Capital Markets. The company was upgraded on Tuesday, May 16 by Loop Capital. BMO Capital Markets has "Buy" rating and $137.0 target. On Thursday, February 1 the company was maintained by Cowen & Co. The firm earned "Neutral" rating on Monday, September 26 by Goldman Sachs.

Other reports by Iphone Fresh

Discuss This Article